Web-Guided System May Benefit Patients With Benign Paroxysmal Positional Vertigo
- byDoctor News Daily Team
- 06 July, 2025
- 0 Comments
- 0 Mins
Patients may benefit from treating Benign paroxysmal positional vertigo (BPPV) themselves using a web-guided system suggests a new study published in the JAMA Neurology.
Benign paroxysmal positional vertigo (BPPV) is the most common cause of vertigo with frequent recurrences.
A study was conducted to determine the efficacy of a web-based diagnosis and treatment of BPPV when it recurs in patients with confirmed and treated Benign paroxysmal positional vertigo (BPPV).
This randomized, controlled, parallel-group, double-blind trial took place in multiple referral-based university hospitals in South Korea between July 2017 and February 2020. Of 728 patients (age ≥20 years) with diagnosed and treated BPPV, 585 were enrolled after excluding 143 who declined participation, could not use the internet, or had spinal problems, multicanal BPPV, or cognitive dysfunction. Patients were followed up for recurrence at least for 2 years until February 2022.
Patients were randomly assigned (1:1) to the treatment or control group. The patients in the treatment group completed a questionnaire for diagnosis and received a video clip for self-administration of canalith repositioning maneuver (CRM) according to the type of BPPV diagnosed when they experienced positional vertigo again. Patients in the control group received a video clip for self-administration of CRM according to the type of BPPV that had been diagnosed on enrollment.
The primary outcome was self-reported resolution of positional vertigo post-CRM. Secondary outcomes included difficulties and requirement for assistance when using the program and any falls or other adverse events related to CRM. The primary outcome was analyzed using both intention-to-treat and per-protocol methods.
Results
Of 585 patients enrolled, 292 were randomized to the treatment group and 293 were randomized to the control group
Overall, 128 (21.9%) had recurrence (58 in the treatment group and 70 in the control group), and 109 (85.2%) successfully used the web-based system.
In the intention-to-treat analysis, 42 of 58 individuals (72.4%) in the treatment group and 30 of 70 individuals (42.9%) in the control group reported vertigo resolution
This trial proved the efficacy of a web-based system for the diagnosis and treatment of recurrent BPPV. Use of this system may play an important role in telemedicine for vestibular disorders.
Reference:
Kim H, Kim J, Choi K, et al. Effect of Self-treatment of Recurrent Benign Paroxysmal Positional Vertigo: A Randomized Clinical Trial. JAMA Neurol. Published online January 17, 2023. doi:10.1001/jamaneurol.2022.4944
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
Eli Lilly plans to build new USD 3 billion facilit...
- 04 November, 2025
Rajkot Maternity Hospital CCTV Leak: How a simple...
- 04 November, 2025
Gland Pharma profit rises 12 percent to Rs 184 cro...
- 04 November, 2025
AIIMS Delhi doctors told to use Hindi in prescript...
- 04 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!